Citations

Clear

941 citation(s) found for "Tefferi, A".

Phase II trial of luspatercept with or without hydroxyurea for the treatment of patients with myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis or unclassifiable with ring sideroblasts.
Mangaonkar, Abhishek A. , Yi, Cecilia Ysabel Arana, Foran, James M. , Geyer, Susan M. , Lola, Erinayo S Baba, Hanson, Jean, Al‐Kali, Aref , Begna, Kebede H. , Elliott, Michelle A. , Gangat, Naseema , Litzow, Mark R. , Wolanskyj-Spinner, Alexandra P., Tefferi, Ayalew , Patnaik, Mrinal M. , Murthy, Hemant S. , Badar, Talha , McCullough, Kristen , Alkhateeb, Hassan B. , Shah, Meera , Wolanskyj, Alexandra P. , Hogan, William J.

Mayo Clinic

Journal of Clinical Oncology | June 6, 2022 | Volume: 40 | Issue: 16_suppl | Pages: TPS7080-TPS7080

10.1200/jco.2022.40.16_suppl.tps7080 Get It

TPS7080 Background: Myelodysplastic syndrome/myeloproliferative neoplasms (MDS/MPN) are classified as a distinct category under the World Health Organization (WHO) classification of myeloid neoplasms. MDS/MPN with RS and thrombocytosis (MDS/MPN-RS-T) and MDS/MPN, unclassifiable with > 15% bone marrow ring sideroblasts (MDS/MPN-U-RS) have similar clinical and pathological characteristics with symptomatic or transfusion-dependent anemia as the predominant morbidity. Luspatercept has been approved in myelodysplastic syndromes with ring sideroblasts (MDS-RS) and MDS/MPN overlap syndromes, based on the phase 3 MEDALIST clinical trial which primarily included MDS-RS patients with an objective erythroid response rate of approximately 40 per cent. In this trial, some MDS-RS patients also experienced an increase in neutrophil and platelet counts. This raises a safety concern for MDS/MPN patients with elevated platelet or WBC counts such as MDS/MPN-RS-T and MDS/MPN-U-RS. Previous studies have shown clinical and biological differences between MDS-RS and MDS/MPN-RS-T, with the latter group at a significantly elevated risk for thrombotic events. Additionally, several MDS/MPN-RS-T patients are on hydroxyurea which may blunt the erythroid response of luspatercept. Therefore, it is imperative to establish the safety and efficacy of luspatercept in this patient group. Methods: This is an investigator-initiated, prospective, phase II study of luspatercept in MDS/MPN overlap neoplasms with ring sideroblasts and thrombocytosis or unclassifiable with ring sideroblasts with 2 arms; hydroxyurea-independent (cohort A) and hydroxyurea-dependent (cohort B). Hydroxyurea and/or aspirin use is allowed as per investigator discretion. The primary goal is to study the efficacy and safety of luspatercept in MDS/MPN-RS-T or MDS/MPN-U-RS with symptomatic anemia. The primary endpoint is to assess erythroid response rate as per the 2015 International Working Group MDS/MPN response criteria. Secondary endpoints include response duration, time to acute myeloid leukemia (AML) transformation, thrombosis rate, AML-free and overall survival. Inclusion criteria include newly diagnosed or relapsed/refractory adult patients with WHO-defined diagnosis of MDS/MPN-RS-T or MDS/MPN-U-RS with symptomatic or transfusion-dependent anemia and unlikely to respond (EPO level > 200 IU/L) or intolerant to erythropoiesis stimulating agent (ESA) therapy. Prior therapy with lenalidomide, hypomethylating agents or immunosuppressive therapy is allowed. The overall plan is to enroll 54 patients across the three Mayo Clinic sites, Minnesota, Arizona and Florida. Enrollment to the trial began in January 2022 with 1 patient enrolled at the time of abstract submission. Clinical trial information: NCT05005182.
Limited activity of fedratinib in myelofibrosis patients relapsed/refractory to ruxolitinib 20 mg twice daily or higher: A real‐world experience
Gangat, Naseema , Al‐Kali, Aref , Begna, Kebede H. , Patnaik, Mrinal M. , Litzow, Mark R. , Shah, Meera , Mangaonkar, Abhishek A. , Foran, James M. , Palmer, Jeanne , Pardanani, Animesh , Tefferi, Ayalew , Al-Kali, Aref , Shah, Mithun V , Mangaonkar, Abhishek A. , Foran, James M , Palmer, Jeanne M., Pardanani, Animesh , Tefferi, Ayalew , McCullough, Kristen , Hogan, William J. , Alkhateeb, Hassan B.

Mayo Clinic

British Journal of Haematology | May 26, 2022 | Volume: 198 | Issue: 4 | Pages: No page available

10.1111/bjh.18284 | PMID 35614565 Get It

Myeloproliferative neoplasms – a global view
Tefferi, Ayalew , Mathews, Vikram , Samuelsson, Jan , Szuber, Natasha , Xiao, Zhijian , Hokland, Peter , Ianotto, Jean-Christophe , Mathews, Vikram , Samuelsson, Jan , Szuber, Natasha , Hokland, Peter , Ianotto, Jean‐Christophe

Mayo Clinic

British Journal of Haematology | April 28, 2022 | Volume: 198 | Issue: 6 | Pages: 953-964

10.1111/bjh.18213 | PMID 35482584 Get It

Real‐world experience with luspatercept and predictors of response in myelodysplastic syndromes with ring sideroblasts
Farrukh, Faiqa, Chetram, Deandra , Al‐Kali, Aref , Foran, James M. , Patnaik, Mrinal M. , Badar, Talha , Begna, Kebede H. , Hook, C. Christopher , McCullough, Kristen , Mangaonkar, Abhishek A. , He, Rong , Gangat, Naseema , Tefferi, Ayalew , Patnaik, Mrinal , Begna, Kebede , Hook, Christopher, McCullough, Kristen B , Mangaonkar, Abhishek A. , He, Rong , Gangat, Naseema , Tefferi, Ayalew , Badar, Talha , Hogan, William J.

Mayo Clinic

American Journal of Hematology | March 16, 2022 | Volume: 97 | Issue: 6 | Pages: No page available

10.1002/ajh.26533 | PMID 35293000 Get It

Mast cell sarcoma: 2 Mayo Clinic cases
Singh, Amritpal , Pardanani, Animesh , He, Rong , Tefferi, Ayalew , Reichard, Kaaren K. , Pardanani, Animesh , He, Rong , Tefferi, Ayalew , Alkhateeb, Hassan B. , Orazi, Attilio

Mayo Clinic

American Journal of Hematology | March 10, 2022 | Volume: 97 | Issue: 10 | Pages: 1381-1383

10.1002/ajh.26525 | PMID 35266568 Get It

Classification of myeloid neoplasms/acute leukemia: Global perspectives and the international consensus classification approach
Arber, Daniel A. , Hasserjian, Robert P. , Mathews, Vikram , Roberts, Andrew W. , Schiffer, Charles A. , Roug, Anne Stidsholt , Tefferi, Ayalew , Mathews, Vikram , Tefferi, Ayalew , Roberts, Andrew W , Arber, Daniel A , Orazi, Attilio , Cazzola, Mario , Döhner, Hartmut

Mayo Clinic

American Journal of Hematology | February 18, 2022 | Volume: 97 | Issue: 5 | Pages: 514-518

10.1002/ajh.26503 | PMID 35179244 Get It

Midostaurin therapy for advanced systemic mastocytosis: Mayo Clinic experience in 33 consecutive cases
Singh, Amritpal , Al‐Kali, Aref , Begna, Kebede H. , Litzow, Mark R. , Larsen, Jeremy T. , Sher, Taimur , Abdelmagid, Maymona, Farrukh, Faiqa, Reichard, Kaaren K. , Gangat, Naseema , Pardanani, Animesh , Tefferi, Ayalew , Abdelmagid, Maymona G

Mayo Clinic

American Journal of Hematology | February 14, 2022 | Volume: 97 | Issue: 5 | Pages: 630-637

10.1002/ajh.26498 | PMID 35156231 Get It

AbstractWe retrospectively examined our experience with midostaurin therapy in 33 consecutive patients (median age 68 years; 58% females) with advanced systemic mastocytosis (adv‐SM): aggressive SM (ASM; n = 17), SM associated with another hematologic neoplasm (SM‐AHN; n = 14) and mast cell leukemia (MCL; n = 2). KITD816V mutation was detected in 84% of the patients and C findings in 91%. Eleven (33%) patients were previously treated with other cytoreductive drugs, including cladribine (n = 4) and imatinib (n = 3). Median time from diagnosis to initiation of midostaurin therapy was 2.2 months (range 0.3–41). Using modified valent criteria, overall response was 42% (53% ASM, 29% SM‐AHN, 50% MCL; p = .22), all classified as being major. Responses included ≥50% reduction in bone marrow mast cells in 40% and normalization of serum tryptase in 29%, of evaluated cases. After a median follow‐up of 14.6 months from initiation of midostaurin therapy, 7 (21%) deaths, 1 (3%) leukemic progression, and 18 (55%) treatment discontinuations were documented; median duration of midostaurin treatment was 7.9 months (range 0.5–123) and response duration 21.5 months (range 2.9–123). Most frequent side effect was gastrointestinal (51%) while grade 3/4 neutropenia or thrombocytopenia occurred in 12% of patients. Response to treatment was not predicted by KIT mutation (p = .67) or exposure to prior cytoreductive therapy (p = .44). Median survival was longer in midostaurin responders but not significantly (median 26.5 vs. 16 months; p = .15). Findings from the current study are broadly consistent with previously published clinical trial observations.